2022 Controlled Substance Prescribing in West Virginia
Executive Summary
West Virginia continues to lead the nation in the opioid epidemic with the highest drug overdose death rate. The West Virginia Board of Pharmacy (BOP), in collaboration with the West Virginia Department of Health and Human Resources (DHHR), Office of Maternal, Child and Family Health (OMCFH), Violence and Injury Prevention Program (WV VIPP), has conducted surveillance using data generated by the Controlled Substance Monitoring Program (CSMP). The CSMP, which is the state’s Prescription Drug Monitoring Program (PDMP), collects data on all controlled substances dispensed in West Virginia.
Despite being at the forefront of the opioid epidemic, West Virginia has made significant strides to reduce this burden through public health surveillance. The WV VIPP received Centers for Disease Control and Prevention (CDC) funding through the Overdose Data to Action (OD2A) cooperative agreement in 2019. An activity under this grant is to improve PDMP infrastructure or information systems to support proactive reporting and data analysis, including enhancing reporting systems to increase frequency and quality of reporting. The CDC provided specific indicators to measure opioid prescribing behaviors during the previous cooperative agreement which continue to be used in the state. The BOP and WV VIPP were interested in modifying these indicators to establish state-specific measures. The results of this analysis were obtained using 2022 CSMP data. To align with the CDC specific indicators, drugs that contain buprenorphine were not included. This document contains a description of the modified indicators and a justification for that modification.
Data Notes
The same methodology was used to classify all data. Percent and Rate ranges are based on the standard deviation (SD) from the mean. The SD is a number used to describe the distribution of measurements. A small SD indicates that most of the measurements are close to the mean, and a large SD indicates that the measurements are more widely spaced from one another. The SDs were used for these indicators to provide information about how each county-specific indicator compared to the others in the rest of the state. Dark green is 1.5 SD from the mean.
Map Notes
Legends are located in the lower left-hand corner of each map. You may click on each county to view its respective opioid indicator. Click on 'expand' in the top right-hand corner of each map to navigate, and zoom in & out.
Opioid Doses per 1,000 State Residents
This indicator was modified to evaluate the actual number of doses, or pills, that were distributed. This information is presented as a rate per 1,000 population. It is important to look at the number of prescriptions being written, as the original indicator measures. However, there is a recent push to write for fewer doses on each prescription, which could lead to an increase in the number of total prescriptions written. Therefore, it is prudent to consider the total number of doses being dispensed to get a more accurate measure of opioid prescribing practices.
Average Duration of Supply
Furthermore, the WV VIPP and BOP were interested in looking at the average day supply of opioids related to this indicator and sought to understand whether there was a correlation between the number of doses being prescribed and the average day supply. In early 2018, the West Virginia Legislature passed Senate Bill 273 (SB 273), which limits the total number of days for which a prescription for an opioid can be written. Looking at the average day supply will help WV VIPP and BOP to determine if SB 273 has an impact.
Compared to 2021, overall opioid doses prescribed decreased across all counties in West Virginia with an average decrease of 3% in 2022. The overall average day supply for opioid prescriptions decreased by 1% from 2021-2022 and the percentage changes ranged from a 5% decrease to a 2% increase at the county level.
Morphine Milligram Equivalent (MME)
This indicator was modified to present another measure of MME. The CDC recommends a dose <50 MME/day and no more than 90 MME/day. The odds of overdose increase from 1.9 to 4.6 when going from 50 to <100 MME/day. [1] It is important to assess this modified indicator to obtain an accurate picture of what counties are at increased risk of overdose.
There was a 6% decrease in high-risk daily dose prescribing across the state. However, changes varied at the county level, with a range of a 19% decrease to 5% increase from 2021-2022.
[1] Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016. MMWR Recomm Rep 2016; 65:1-46 DOI:http://dx.doi.org/10.15585/mmwr.rr6501e1
Prescriber "Shopping"
The BOP has provided unsolicited reporting of patients with 8 or more prescribers within a 6-month period for the past few years and was interested in comparing this to the CDC guidelines which is 5 or more prescribers within a 6-month period. In December 2016, DHHR, in collaboration with the BOP, produced a report of the 2016 overdose deaths. It was found that the decedents were 3 times more likely to have seen 3 or more prescribers. WV VIPP and BOP were interested in evaluating this measure for the overall CSMP population.
Pharmacy "Shopping"
The BOP has provided unsolicited reporting of patients with 5 or more pharmacies within a 6-month period for the past few years, which is the same as the CDC indicators. In December 2016, DHHR, in collaboration with the BOP, produced a report of the 2016 overdose deaths. It was found that the decedents were 70 times more likely to have used 4 or more pharmacies. WV VIPP and BOP were interested in evaluating this measure for the overall CSMP population.
Compared to 2021, the rate of patients seeing 3 or more prescribers increased across all counties in the state with a percentage increase of 7%. However, the rate of patients that went to 4 or more pharmacies decreased by 5% across the state.
Long-Acting/Extended-Release Opioids
The CDC recommends the initial opioid prescription be short-acting/immediate release as a strategy to reduce the risk of overdose. The WV VIPP and BOP chose to review the percent of patients prescribed long-acting opioids when said patients were opioid-naïve (i.e., no opioids in the previous 45 days). The percent of patients who were opioid-naïve and prescribed short-acting opioids were also reviewed. Even at low doses of immediate release opioids, the potential for misuse and risk of overdose increases if the patient is not counseled on how to take the medication safely. However, it was determined that efforts should be focused on those patients who received long-acting opioids.
There was an overall increase in the percent of patients who were opioid-naïve from 2021 to 2022 with a 7% increase. Percentage changes ranged from a 43% decrease to a 164% increase among counties.
Overlapping Opioid & Benzodiazepine Prescriptions
This indicator was modified to assess the percent of patients who had overlapping opioid and benzodiazepine prescriptions. Overlapping opioids with benzodiazepines increase the risk of overdose. The WV VIPP and BOP wanted to determine the difference between overlapping days and distinct patients and whether the counties of interest were the same between the two.
Compared to 2021, there was an overall decrease in the percent of patients who had an overlapping opioid and benzodiazepine prescription in 2022 with a 15% decrease. Percentage changes ranged from a 50% decrease to a 51% increase among counties.
Conclusion
Modifying the CDC indicators to answer state specific measures and questions is important to get a better picture of the prescribing patterns in the state. The results of these modified indicators are different from the CDC required indicators. This will provide opportunities to conduct further research/analysis on certain topics of interest, determine high-risk areas in the state, and provide appropriate prescriber education and intervention.
2021 Story Map
CSMP Data Dashboard
Contact
For more information regarding any of these reports or the West Virginia Board of Pharmacy’s Controlled Substance Monitoring Program (CSMP), please see contact information below.
- Justin Lee, CSMP Epidemiologist
- Phone: (304) 414 - 0537
- E-mail: Justin.A.Lee@wv.gov
- Brandon Williams, CSMP Epidemiologist
- Phone: (304) 414 - 0633
- E-mail: Brandon.K.Williams@wv.gov
- Nathan Wood, CSMP Epidemiologist
- Phone: (304) 414 - 0789
- E-mail: Nathan.G.Wood@wv.gov
- Allison Humphreys, Board of Pharmacy Graphic Designer
- Phone: (304) 414 - 0799
- E-mail: Allison.R.Humphreys@wv.gov
- Mike Goff, Board of Pharmacy Director
- Phone: (304) 558 - 0558
- E-mail: Michael.L.Goff@wv.gov